Your situation (severe hypercholesterolemia short-circuits the risk score) 10-yr PREVENT-ASCVD ≥10% (high)
risk-10plusNo one has reached this rule yetHigh-intensity statin; LDL-C <70, non-HDL-C <100
No clinician has signed off this rule yet. It reflects our reading of the guidelines cited below, which has not been independently checked.
Word for word, as generated for the example person below. Figures in the text are theirs.
A high-intensity statin should be started, aiming for LDL-C below 70 mg/dL (and non-HDL-C below 100).
Expert guidelinesOfficial guidelines recommend it, based on trials plus expert judgment.
Your estimated 10-year PREVENT-ASCVD risk is 13.2%, which is the guideline's "high risk" category — 10% or above. This is the primary-prevention group that carries the same LDL goal as established disease, and where a high-intensity statin rather than a moderate one is the starting point.
ACC/AHA (US)
A high-intensity statin should be started, aiming for LDL-C below 70 mg/dL (and non-HDL-C below 100).
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia · Recommendation behind this rule · class and level read from the guideline tables on 2026-09-30
The LDL-C goal below 70 (non-HDL-C below 100)
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia · Graded separately within the same recommendation · class and level read from the guideline tables on 2026-09-30
ESC (Europe)
At high risk, at least a 50% LDL-C cut and a goal below 70 mg/dL. The ESC sorts risk with SCORE2, not the PREVENT equations used here, so the tiers line up only roughly.
2019 ESC/EAS dyslipidaemia guidelines · Recommendation tables · class and level read from the guideline tables on 2026-09-30
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia · Class 1 · Level A
Your risk-enhancing factors reinforce this: Diabetes, age over 40.
Expert guidelinesOfficial guidelines recommend it, based on trials plus expert judgment.
At this risk level they do not change whether to treat — that is already settled — but they matter for how hard, and for whether an add-on is needed to reach goal.
ACC/AHA (US)
The guideline grades risk enhancers only for borderline risk (Class 2a, B-NR). Using them to set intensity at higher risk is this tool's reading.
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia · Recommendation behind this rule · carried over from an earlier review, not yet re-read
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia
“Atrial fibrillation, blood thinner not yet discussed” — an illustrative profile, not a real user.
Asked after: No known cardiovascular disease
Cited by the recommendations above.
A trial that could change this, still running or reported too recently to be settled.
For practising clinicians. Endorse it, propose a change, or dispute it. We verify every reviewer before a review is shown, and a review stays attached to the version of the rule you saw — if the rule changes, the page says so. You'll be asked to declare any relevant interests; they're shown with your review.
Log in or create an account to submit a review. An account is how we tie a review to a person we can verify.
Runs in lib/engine/lipidPathway.ts as risk-10plus.